These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 6141599

  • 1. Modulation of CNS dopamine receptors by peptides.
    Mishra RK.
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):437-42. PubMed ID: 6141599
    [Abstract] [Full Text] [Related]

  • 2. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
    Chiu P, Rajakumar G, Chiu S, Johnson RL, Mishra RK.
    Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
    [Abstract] [Full Text] [Related]

  • 3. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S, Paulose CS, Mishra RK.
    Science; 1981 Dec 11; 214(4526):1261-2. PubMed ID: 6117947
    [Abstract] [Full Text] [Related]

  • 4. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
    Bhargava HN.
    Neuropharmacology; 1984 Apr 11; 23(4):439-44. PubMed ID: 6145116
    [Abstract] [Full Text] [Related]

  • 5. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Rajakumar G, Naas F, Johnson RL, Chiu S, Yu KL, Mishra RK.
    Peptides; 1987 Apr 11; 8(5):855-61. PubMed ID: 2893360
    [Abstract] [Full Text] [Related]

  • 6. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Chiu S, Paulose CS, Mishra RK.
    Peptides; 1981 Apr 11; 2(1):105-11. PubMed ID: 6113579
    [Abstract] [Full Text] [Related]

  • 7. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN.
    Life Sci; 1984 Feb 27; 34(9):873-9. PubMed ID: 6142397
    [Abstract] [Full Text] [Related]

  • 8. Chronic haloperidol-amphetamine interactions and mesolimbic dopamine.
    Lynch MR, Kuhn HG, Carey RJ.
    Neuropsychobiology; 1988 Feb 27; 19(2):97-103. PubMed ID: 3226530
    [Abstract] [Full Text] [Related]

  • 9. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
    Mishra RK.
    Nutr Health; 1984 Feb 27; 3(3):175-87. PubMed ID: 6152723
    [Abstract] [Full Text] [Related]

  • 10. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
    Kostrzewa RM, Saleh MI.
    Neuropharmacology; 1989 Aug 27; 28(8):805-10. PubMed ID: 2571103
    [Abstract] [Full Text] [Related]

  • 11. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
    Staunton DA, Magistretti PJ, Shoemaker WJ, Deyo SN, Bloom FE.
    Brain Res; 1982 Jan 28; 232(2):401-12. PubMed ID: 6322915
    [Abstract] [Full Text] [Related]

  • 12. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M, Krejcí I, Kasafírek E, Schuh J, Dlabac A.
    Pol J Pharmacol Pharm; 1985 Jan 28; 37(3):311-5. PubMed ID: 2866500
    [Abstract] [Full Text] [Related]

  • 13. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
    Seeger TF, Thal L, Gardner EL.
    Psychopharmacology (Berl); 1982 Jan 28; 76(2):182-7. PubMed ID: 6805029
    [Abstract] [Full Text] [Related]

  • 14. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
    Srivastava LK, Bajwa SB, Johnson RL, Mishra RK.
    J Neurochem; 1988 Mar 28; 50(3):960-8. PubMed ID: 2892892
    [Abstract] [Full Text] [Related]

  • 15. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
    Ott MC, Mishra RK, Johnson RL.
    Brain Res; 1996 Oct 21; 737(1-2):287-91. PubMed ID: 8930377
    [Abstract] [Full Text] [Related]

  • 16. Striatal dopamine receptor function in morphine-tolerant dependent rats: influence of hypothalamic peptides.
    Bhargava HN.
    NIDA Res Monogr; 1984 Mar 21; 49():320-6. PubMed ID: 6148693
    [No Abstract] [Full Text] [Related]

  • 17. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats.
    Pulvirenti L, Kastin AJ.
    Eur J Pharmacol; 1988 Jul 07; 151(2):289-92. PubMed ID: 2901971
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.
    Csernansky JG, Glick S, Mellentin J.
    Psychopharmacology (Berl); 1987 Jul 07; 91(4):440-4. PubMed ID: 3108924
    [Abstract] [Full Text] [Related]

  • 19. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.
    Prosser ES, Pruthi R, Csernansky JG.
    Psychopharmacology (Berl); 1989 Jul 07; 99(1):109-16. PubMed ID: 2506596
    [Abstract] [Full Text] [Related]

  • 20. Chronic lithium administration has no effect on haloperidol-induced supersensitivity of pre- and postsynaptic dopamine receptors in rat brain.
    Reches A, Wagner HR, Jackson V, Fahn S.
    Brain Res; 1982 Aug 19; 246(1):172-7. PubMed ID: 6289974
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.